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Despite the importance of the cytokine receptor flt3 in dendritic cell (DC) homeostasis, little is known about its
regulation during DC development. In this issue of Immunity, Carotta et al. (2010) reveal that the transcription
factor PU.1 controls Flt3 expression in hematopoietic progenitors in a dose-dependent manner.Since their original identification in the
1970s (Steinman and Banchereau,
2007), the ontogeny of dendritic cells
(DCs) has been the center of controversy.
Seminal studies in the recent years have
now established DCs as a distinct hema-
topoietic lineage of the mononuclear
phagocyte system specialized in the con-
trol of tissue immunity (Merad and Manz,
2009). The successive DC commitment
steps in the bone marrow include com-
mon myeloid progenitors (CMPs) and
macrophage-DC progenitors (MDPs). It
is at the level of the MDP that DCs
separate from the monocyte-macro-
phage lineage. MDPs, which have lost
the potential to give rise to granulocytes,
erythrocytes, and megakaryocytes, sub-
sequently give rise to monocytes and to
the common DC precursor (CDP). CDPs
give rise to classical DC-restricted pre-
cursors called (pre-DCs) and plasmacy-
toid DCs in the bone marrow but have
lost the potential to give rise to mono-
cytes. Pre-DCs leave the bone marrow
and circulate through the blood to home
to lymphoid organs where they differen-
tiate into lymphoid (Merad and Manz,
2009) and nonlymphoid tissue resident
DCs (Helft et al., 2010). Previous data
have also shown that common lymphoid
progenitors can give rise to DCs; how-
ever, the exact contribution of this lineage
to DC homeostasis in secondarylymphoid organs and nonlymphoid
tissues in vivo remains to be determined
(Merad and Manz, 2009).
The cytokine fms-like thyrosine kinase
3 ligand (Flt3L) and its receptor (Flt3)
are key regulators of DC commitment in
hematopoiesis. Flt3 is expressed on
short-term repopulating hematopoietic
stem cells and is progressively extin-
guished on most hematopoietic lineages
with the exception of the DC precursors
(Merad and Manz, 2009). Loss of Flt3
expression in hematopoietic progenitors
correlates with the loss of DC differentia-
tion potential, whereas enforcement of
Flt3 expression on Flt3-negative progeni-
tors rescues their ability to differentiate
into DCs (Onai et al., 2006). The cytokine
Flt3L is ubiquitously secreted by multiple
tissue stroma and endothelial cells and
by activated T cells (Schmid et al., 2010).
Flt3L as a single cytokine is sufficient to
drive the differentiation of mouse and
human hematopoietic bone marrow pro-
genitors into DCs in vitro (Schmid et al.,
2010). Consistently, mice that are defi-
cient in Flt3L have reduced numbers of
pre-DCs and DCs in lymphoid organs
and nonlymphoid tissues (Helft et al.,
2010). Despite the importance of Flt3 in
DC development, there is surprisingly
little known about how Flt3 expression is
controlled in hematopoiesis. In this issue
of Immunity, Carotta et al. (2010) demon-strate that PU.1 directly controls Flt3 gene
expression on hematopoietic progenitors
in a dose-dependent manner.
The role of PU.1 in DC differentiation
has been suggested more than a decade
ago as mice that lacked PU.1 showed
defects in DC development (Merad and
Manz, 2009). Similar results were ob-
tained with knockdown of PU.1 in human
CD34+ fetal liver precursors (Merad and
Manz, 2009). However, the early lethality
of PU.1-deficient mutant mice precluded
investigations on the role of PU.1 in DC
homeostasis during adult life. Thus it
remains unknown whether PU.1 functions
within the DC lineage or whether its role in
DC differentiation is a consequence of its
role in early myelopoiesis. Previous work
by the same group has shown that PU.1
ablation have distinct effects during adult
and fetal hematopoiesis and revealed that
in contrast to PU.1-deficient embryos,
PU.1 elimination in adults leads to
increased granulopoiesis, suggesting that
PU.1 expression restricts GMP differenti-
ation into granulocytes therefore favoring
the differentiation of the monocyte-DC
lineage (Dakic et al., 2007). In addition, en-
forced expression of PU.1 in hematopietic
progenitors suggested a dose-dependent
role of PU.1 in specifying DC and macro-
phage fate (Bakri et al., 2005; Laiosa
et al., 2006). However, the exact role of
endogenous amounts of PU.1 in adult32, May 28, 2010 ª2010 Elsevier Inc. 583
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Figure 1. Role of PU.1 in DCpoiesis
PU.1 directly binds to the Flt3 gene and controls
Flt3 mRNA and protein expression. Flt3 engage-
ment by Flt3 ligand (Flt3L) also leads to PU.1
expression (Onai et al., 2006), suggesting that
PU.1 and Flt3 form a positive feedback loop to
maintain high Flt3 expression levels on hematopoi-
etic progenitors.
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addressed.
Carotta et al. now reveal that condi-
tional ablation of PU.1 allele in adult
mice abolished Flt3 expression on bone
marrow and spleen hematopoietic pro-
genitors and prevented their differentia-
tion into classical and plasmacytoid
spleen DCs in a cell-intrinsic manner
in vivo. They also showed that PU.1 inac-
tivation in CMP, CLP, and CDP abolished
their DC differentiation potential in vitro
in Flt3L-supplemented cultures. They
revealed direct binding of PU.1 with con-
served regions of the promoter and the
first intron of the Flt3 gene and showed
that PU.1 controls Flt3 mRNA and protein
expression on hematopoietic progenitors
in a dose-dependent manner.
These results came as a surprise given
that previous studies have shown that
enforced expression of Flt3 in Flt3-nega-
tive hematopoietic progenitors such as584 Immunity 32, May 28, 2010 ª2010 Elsevimegakaryocyte and erythrocyte progeni-
tors (MEPs), induced PU.1 expression,
and rescued MEP DC differentiation
potential leading to the hypothesis that
PU.1 was downstream Flt3 signaling
(Onai et al., 2006). However, these data
have also shown that enforced PU.1 in
MEP progenitors increased Flt3 mRNA
and increased responsiveness to Flt3L
(Onai et al., 2006), which is consistent
with the data shown by Carotta et al. Alto-
gether, these results might suggest that
PU.1 and Flt3 form a positive feedback
loop aiming at controlling cytokine sensi-
tivity threshold and DC commitment in
hematopoiesis (Figure 1).
The process of development from
pluripotent hematopoietic progenitors
to mature cells with specific functions
involves the progressive loss of develop-
mental potential to other lineages (Schmid
et al., 2010). This stepwise developmental
process has been considered linear in the
sense that once a cell has made a devel-
opmental choice, it cannot revert. A major
area of conundrum in the hematopoiesis
field has been whether cytokines can
instruct lineage commitment or whether
their actions are simply permissible,
allowing the survival and expansion of
already committed cells. In the presence
of saturating concentration of cytokines,
recent studies have established the
instructive role of cytokines on lineage
fate decision (Schmid et al., 2010). In
more physiological conditions, it is likely
that both cytokine concentration and
receptor expression determine whether
a progenitor receives a sufficiently high
signal to differentiate into a particular
lineage (Schmid et al., 2010). MDP
express receptors for the macrophage
colony stimulating factor (M-CSF) and
Flt3L and are able to differentiate into
monocytes and DCs (Merad and Manz,
2009). PU.1 expression together with
Flt3L availability in the microenvironment
may therefore cooperate to provide suffi-
cient Flt3 strength to control MDP differ-
entiation into CDPs rather than mono-
cytes and it will be most interesting to
examine whether MDP progression to
CDPs is affected by the absence of PU.1.
Flt3 expression is maintained in DCs
that populate lymphoid and nonlymphoid
tissues, and Flt3L has been shown to
control the proliferation and homeostasis
of peripheral tissue DCs (Merad and
Manz, 2009). Carotta et al. show thater Inc.PU.1 is maintained at high amounts in
mature DCs and that PU.1 ablation also
decreases Flt3 expression in mature
splenic DCs. However, Flt3 expression on
mature splenic DCs was analyzed 4 days
after PU.1 ablation. Because the half-life
of splenic DCs is approximately 1.5 days
(Merad and Manz, 2009), it is possible
that the reduction of Flt3 expression
observed in these cells reflects PU.1
modulation of Flt3 expression in myeloid
progenitors and their newly formed splenic
DC progeny rather than PU.1 directs regu-
lation of Flt3 expression in splenic DCs.
Recent studies have established that
peripheral tissues are populated by func-
tionally distinct DC populations. These
include plasmacytoid DCs, lymphoid
tissue SIRPa CD8+ DCs, and the related
SIRPa CD103+ DCs in nonlymphoid tis-
sues as well as lymphoid tissue SIRPa+
CD8 DCs and nonlymphoid tissue
SIRPa+ CD103 DCs (Helft et al., 2010).
It is interesting that PU.1 inactivation
affected the differentiation of all DC sub-
sets, whereas PU.1 haplo-insufficiency
affected mostly the differentiation of
hematopoietic progenitors into classical
DCs, particularly the SIRPa DCs in vitro.
SIRPa DCs are much more affected
than SIRPa+ DCs in Flt3/ mice and are
absent in Irf8/ mice, whereas SIRPa+
DCs are unaffected in these mice. There-
fore the more stringent effect of PU.1 defi-
ciency in SIRPa DCs observed by Car-
otta et al. may reflect PU.1 modulation of
Flt3 expression but also PU.1 interaction
with the transcription factor IRF8 (Dakic
et al., 2007). In contrast, plamacytoid DCs
that are also critically dependent on Flt3L
for their development (Merad and Manz,
2009) expressed low PU.1 transcripts
in vivo. Plasmacytoid DC development is
inhibited by granulocyte macrophage
colonystimulating factor (GM-CSF) (Merad
and Manz, 2009) and because PU.1 also
controls GM-CSF receptor expression
(Dakic et al., 2007), it is likely that PU.1
downregulation is required for plasmacy-
toid DC differentiation to proceed. Under-
standing the pattern of expression and
the effect of targeted PU.1 disruption in
peripheral DC populations should help
understand the regulatory pathways that
control the differentiation of these function-
ally distinct DC populations.
Monocytes participate to the nonlym-
phoid tissue DC pool in steady state
conditions and is a major source of DCs
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Previewsin inflamed tissues (Helft et al., 2010).
Previous studies have shown that en-
forced PU.1 expression in monocytes
pushes them toward DC differentiation
(Bakri et al., 2005; Laiosa et al., 2006).
However, the role of endogenous PU.1
levels in monocyte-derived DC differenti-
ation in the steady state and in the inflam-
matory settings remains to be examined
in details.
Importantly, enforced Flt3 expression in
PU.1-deficient progenitors did not rescue
DC differentiation in vivo, suggesting that
PU.1 control of DC differentiation is not
limited to the regulation of Flt3 expres-
sion. PU.1 modulates the expression of
receptors for the cytokines M-CSF and
GM-CSF and interacts with the transcrip-
tions factors IRF-4, IRF-8, and CEBP-a
(Dakic et al., 2007). Modulation of these
molecules could affect DC lineage
commitment, DC differentiation, and DC
homeostasis in the periphery (Merad and
Manz, 2009). Elimination of PU.1 specifi-
cally in early myeloid precursors, DC-committed precursors, and mature DCs
should help delineate the exact role of
PU.1 at different stage of DC differentia-
tion in vivo.
Although large amounts of clinical and
experimental data support the clinical
use of DC vaccines, these data have
also showed that current DC vaccines
are not optimal for the treatment of human
disease (Steinman and Banchereau,
2007). The increasing evidence that DCs
are functionally specialized could and
should be utilized to improve DC vaccine
efficacy in patients. However, in order to
generate functionally specialized DCs de
novo, for example from MDPs, CDPs, or
monocytes, it is critical that the correct
environmental cues are present to ensure
accurate differentiation program. Thus
the ability to recreate DC developmental
programs in vitro is dependent upon our
success in defining these programs
in vivo. Understanding how DC differenti-
ation is controlled will be an essential step
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Is transforming growth factor-b (TGF-b) required for induction of the transcription factor Foxp3 in developing
thymocytes? Ouyang et al. (2010) demonstrate that TGF-b in the thymus prevents deletion of Foxp3+
regulatory T cells.Transforming growth factor-b (TGF-b) is
a regulatory cytokine that has pleiotropic
effects on many different cells types
(Li and Flavell, 2008). Although TGF-b
exists in three isoforms, TGF-b1 is the
predominant form expressed in the
immune system. Active TGF-b signals by
binding simultaneously to two transmem-
brane serine-threonine kinase receptors,
TGF-b receptor I (TGF-bRI) and TGF-b
receptor II (TGF-bRII). TGF-b elicits
diverse cellular responses that are pri-
marily mediated through the actions of
the Smad family of transcription factors,
but TGF-b can also signal via Smad-inde-pendent pathways. The phenotype of
TGF-b1-, TGF-bRI-, and TGF-bRII-defi-
cient animals closely resembles that of
animals deficient in the transcription
factor Foxp3 that lack regulatory T (Treg)
cells, and all mutant strains develop
a lethal autoimmune syndrome and die
at 3–4 weeks of age. Given that TGF-b
plays a critical role in the induction of
Foxp3+ T cells in vitro and in extrathymic
sites in vivo, these studies have raised
the possibility that TGF-b may play a role
in the induction of Foxp3+ T cells during
thymic development. Although this ques-
tion might be easily addressed by analysisof Treg cell populations in TGF-b1-defi-
cient mice, these mice have relatively
normal numbers of Treg cells in the thy-
mus before inflammation develops (Marie
et al., 2005), given that they receive
maternal TGF-b protein from their
mother’s milk. A potential role for TGF-b
in the induction of the development of
Foxp3+ Treg cells in the thymus of TGF-
bRI-deficient mice has been described
(Liu et al., 2008). In this issue of Immunity,
Ouyang et al. (2010) use TGF-bRII-defi-
cient mice and present an alternative
model by demonstrating that TGF-b is
critical for the development of Foxp3+32, May 28, 2010 ª2010 Elsevier Inc. 585
